Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas.

@article{Forrer2013RadioimmunotherapyW1,
  title={Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas.},
  author={Flavio Forrer and Catharina Oechslin-Oberholzer and Benedetta Campana and Richard Herrmann and Helmut R. Maecke and Jan Mueller-Brand and Andreas Lohri},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2013},
  volume={54 7},
  pages={1045-52}
}
UNLABELLED The aim of this study was to determine the maximum tolerated dose (MTD) and to explore the clinical response to (177)Lu-DOTA-rituximab in the treatment of patients with relapsed follicular, mantle cell, or other indolent lymphomas such as marginal zone lymphoma. METHODS To evaluate the MTD, we adjusted the dosage of the radiopharmaceutical according to body surface area (BSA). RESULTS The MTD using (177)Lu-DOTA-rituximab was 1,665 MBq/m(2) of BSA. Thrombocytopenia and leukopenia… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Assessment of cell death mechanisms triggered by 177Lu-anti-CD20 in lymphoma cells.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine • 2018
View 2 Excerpts

MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2016
View 2 Excerpts

Similar Papers

Loading similar papers…